Status:
COMPLETED
Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19
Lead Sponsor:
Centre Leon Berard
Conditions:
Cancer
COVID
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Evaluation of the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection using an IgG serological assay (EUROIMMUN Anti-SARS-Cov2 EL...
Detailed Description
The Bio-Rad SARS-CoV-2 ddPCR Test is a reverse transcription (RT) droplet digital polymerase chain reaction (ddPCR) test designed to detect RNA from SARS-CoV-2 in specimens (mainly nasopharyngeal, ant...
Eligibility Criteria
Inclusion
- Age ≥ 18 years on the day of signing informed consent.
- Confirmed diagnosis of any type of solid or hematologic tumor.
- Ongoing anticancer treatment at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure).
- Suspicion of COVID-19 infection. Patients must not have underwent diagnostic test and/or chest imaging before inclusion.
- Covered by a medical/health insurance.
- Signed and dated IRB/ICE approved informed consent form.
Exclusion
Key Trial Info
Start Date :
November 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04510454
Start Date
November 2 2020
End Date
October 12 2021
Last Update
December 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Leon Berard
Lyon, France, 69008